In line with Tecrea’s mission to provide cell and tissue delivery nanotechnology that translates to the clinic, we are very pleased to announce that one of our partner companies, Blueberry Therapeutics Ltd, has gained final ethical and regulatory approval to conduct a Phase I/II proof of concept clinical trial in humans.In this study, a Nanocin™-based nanomedicine will be tested for safety, local toleration, systemic and local pharmacokinetics as well as efficacy in the chronic and frequently recurrent conditions of onychomycosis and tinea pedis. This progress validates the suitability of Nanocin™ technology for clinical development projects.
Dr Mike Davies, Chief Medical Officer and Co-founder of Blueberry Therapeutics says “This is exciting news and is a major milestone after the tremendous work done by the Blueberry team using Tecrea’s Nanocin™ technology. We eagerly await the preliminary results in Summer that will feed into our IND in the US. Thank you to everybody who has been involved in the development of this unique product”.